Related Experiment Video
Updated: Sep 12, 2026

09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Radiation-free or Chemo-free: Rethinking the Best Strategy for PD-L1-High, Unresectable Stage III NSCLC
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Science and Peking Union Medical College Beijing China.
Precision Radiation Oncology
|September 11, 2026
Abstract:
This article discusses the emerging radiotherapy-free and chemo-free strategies in PD-L1-high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de-escalation without compromising curability.
